The Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) drugs in development market research report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) by six companies/universities/institutes. The top development phase for Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) is preclinical with five drugs in that stage. The Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) pipeline products market are: Gain Therapeutics, Dorphan and Esteve Pharmaceuticals.

The key targets in the Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) pipeline products market include Beta Galactosidase (Acid Beta Galactosidase or Lactase or Elastin Receptor 1 or GLB1 or EC 3.2.1.23), and N-Acetylgalactosamine 6 Sulfatase (Chondroitinsulfatase or Chondroitinase or Galactose 6 Sulfate Sulfatase or N Acetylgalactosamine 6 Sulfate Sulfatase or GALNS or EC 3.1.6.4).

The key mechanisms of action in the Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) pipeline product include Beta Galactosidase (Acid Beta Galactosidase or Lactase or Elastin Receptor 1 or GLB1 or EC 3.2.1.23) Activator with four drugs in Preclinical. The Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) pipeline products include one routes of administration with the top ROA being Oral and four key molecule types in the Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) pipeline products market including Small Molecule, and Fusion Protein.

Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome ) overview

Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is a progressive condition that mainly affects the skeleton. The symptoms vary among affected individuals. The signs and symptoms of MPS IV usually become apparent during early childhood. Affected individuals develop various skeletal abnormalities, including short stature and “knock knees”.

For a complete picture of Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome )’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.